1 Supplementary Methods and Results

2 1. A new assay for phosphorylated tau protein (p-tau) in human plasma, which can

3 detect both N- and C-terminally truncated p-tau181 (mid-p-tau181)

As shown in Supplementary Figure 1, an anti-tau mouse monoclonal antibody against a 4 5 mid-portion of tau protein ranging from 151 to 163 amino acid residues was coupled to 6 paramagnetic beads (Quanterix) and used for the capture antibody. As a detector, we 7 used the AT270 mouse monoclonal antibody (Invitrogen) specific for the threonine 181 8 phosphorylation site. The detection antibody was conjugated to biotin following the 9 manufacturer's instructions (Quanterix). We used the human p-tau181 standard in the 10 Tau (Phospho) [pT181] Human ELISA Kit (Invitrogen) as the calibrator for our mid-p-11 tau181 assay. All plasma samples were diluted four times with the Tau Calibrator 12 Diluent (Quanterix) prior to the assays to minimize matrix effects. The assay procedure

13 followed that for the pTau-181 Advantage V2.1 Kit, except for changes to the capture

14 antibody used as mentioned above. The details of the assay procedures have been

15 described previously (Shinomoto et al. 2021; Satoh-Asahara et al. 2022). All plasma

16 samples were run in duplicate with the same lot of standards. Fluorescent signals were

17 converted to average enzyme per bead (AEB) numbers as described previously (Tatebe

et al. 2017) and then concentrations of plasma mid-p-tau181 were extrapolated from

19 four-parametric logistic curves of AEBs generated with known calibrator

20 concentrations.

21 Plasma mid-p-tau181 levels were measured using the previously described assay 22 on the Simoa HD-X Analyzer (Quanterix) at the National Institutes for Quantum 23 Science and Technology. To ensure that measurements were performed in a blinded 24 manner, unique identifiers that did not contain any participant-related information were 25 attached to the blood sample tubes sent from the clinical department to the investigator 26 who measured the plasma mid-p-tau levels. The samples were decoded only after data sharing with the participating clinical scientists had been completed. Internal quality 2728 control samples were analyzed in duplicates at the start and end of each run to 29 determine within- and between-run variations.

30

31 2. Validation of the newly developed mid-p-tau181 assay

32 2-1. Standard curve for the mid-p-tau181 immunoassay

33 Supplementary Figure 2 shows the standard curve for our novel mid-p-tau181 assay,

34 demonstrating that mid-p-tau181 was detected with high sensitivity. The curve was

35 generated by analyzing the p-tau181 standard in the Tau (Phospho) [pT181] Human

36 ELISA Kit (Invitrogen) in duplicate measures and fitting the digital signals on a four-

- 1 parameter logistic curve. The goodness of fit was 0.9999.
- 2

3 2-2. Limit of detection (LOD) and lower limit of quantification (LLOQ)

4 We prepared 16 aliquots of blank sample (Tau Calibrator Diluent) and measured

5 "background" signals of our novel plasma mid-p-tau181 assay on the Simoa HD-X

6 Analyzer (Quanterix). Signals measured on the Simoa Analyzer were quantified by a

7 common unit, namely average number of enzymes labels per bead (AEB). Thereafter,

- 8 the LOD of the assay was determined as an interpolated mid-p-tau181 concentration
- 9 derived from the mean plus 2.5 SD value of AEBs for the blank samples. The LOD of

10 the assay, which requires 50 μ L of plasma, was 0.1144 pg/mL.

11 The LLOQ of the assay was determined as an interpolated p-tau concentration 12 derived from the mean plus 10 SD value of AEBs for blank samples. The LLOQ of the 13 assay was 0.3770 pg/mL.

14

15 **2-3. Intra-assay precision**

Twenty samples with different concentrations (0.039, 6.25, 25, and 100 pg/mL) of recombinant p-tau181 were prepared for analysis of intra-assay precision, and measured AEBs in one experiment. Intra-assay precision was determined by calculating withinrun coefficient of variation (CV) for those samples.

- Intra-assay precision was robust with CVs between 1.1% and 3.5 %
 (Supplementary Table 1).
- 22

23 2-4. Inter-assay precision for quality controls and repeatability of the standard 24 curve

We prepared three recombinant p-tau samples and two plasma samples with different plasma mid-p-tau181 concentrations for quality control experiments and measured the mid-p-tau181 levels in those samples five times on different days. Interassay precision was determined by calculating the CV of the AEB signals between the runs for those samples.

The %CV of the AEBs at different concentrations were 5.56, 5.09, 9.19, 5.30, and
5.96 %, respectively (Supplementary Table 2). These results indicated that our novel
mid-p-tau181 assay showed good inter-assay precision (< 10%).

33

34 **2-5. Dilution linearity**

- 35 To explore dilution linearity, a plasma sample with a moderate mid-p-tau181
- 36 concentration was used, and twofold serial dilutions ($\times 2$, $\times 4$, $\times 8$, $\times 16$, and $\times 32$) of the

1 sample were generated using the sample diluent until the theoretical concentration

2 reached the LLOQ. Serially diluted samples were analyzed in duplicate.

- 3 The dilution linearity experiments demonstrated that an examined sample can be
- 4 diluted to a concentration just below the LLOQ and still provide a reliable
- 5 quantification after the serial dilution (Supplementary Figure 3).
- 6 7

2-6. Spike recovery and parallelism

8 For the spike recovery tests, four aliquots of each two plasma samples with different 9 mid-p-tau181 concentrations were prepared and spiked with 0, 0.15, 0.3, and 0.6 pg of 10 mid-p-tau181 in 360 µL of solution (containing patient plasma, sample buffer, and 11 spiked peptide). These eight (4×2) aliquots were analyzed in quadruplicate on the same 12 run. To evaluate parallelism, two spike recovery curves were made, starting from the 13 non-spiked solution to the 0.6 pg-spiked solution. Recovery rates (%Recovery) were 14 calculated by subtracting the endogenous mid-pTau181 concentration from the 15 measured concentration (Andreasson U, et al. Front Neurol. 2015; 6: 179).

In the spike recovery and parallelism experiments (Supplementary Figure 4), the recovery rate (%Recovery) of each sample was 84.4%–119.3% (Supplementary Table 3). The parallelism of two spike recovery curves starting from the non-spiked solution to the 0.6 pg-spiked solution is also shown in Supplementary Figure 4, with our data demonstrating that plasma samples spiked with 0, 0.15, 0.3, and 0.6 pg of mid-ptau181 protein provided reliable recovery rates and parallelism.

22

23 2-7. Comparison of AEB signals for N- and C-terminally truncated p-tau181

between the established p-tau181 assay and the new mid-p-tau181 assay developed herein

- 26 To confirm the ability of our new mid-p-tau assay to detect both N- and C-terminally
- 27 truncated p-tau proteins, we compared our assay with the widely used and commercially
- available p-tau181 assay (Simoa[™] pTau-181 Advantage V2 Kit, Quanterix). We
- 29 prepared both N- and C-terminally truncated p-tau proteins as described in the
- 30 following sections.

31

32 2-7-1. cDNA construction

33 The cDNA of tau (aa100–251) was generated from N Δ R cDNA in PCI-neo (Takashima

- et al. 1998) according to the modified instructions of the PrimeSTAR® Mutagenesis
- 35 Basal Kit (Takara Bio Inc., R046). Briefly, 2.5 ng of N Δ R cDNA was mixed in 1×
- 36 PrimeSTAR® Max DNA Polymerase (Takara Bio Inc., R045) containing 0.2 µM of

2 µM of reverse primer (5'-GTGGTTCCCATGGTGGCGAATTCTCGAGGCTAG-3'). 3 PCR was performed on a C1000[™] Thermal Cycler (BIO-RAD) with the following 4 steps: an initial denaturation at 98°C for 2 min; 18 three-step cycles involving 5 denaturation at 98°C for 10 s, annealing at 55°C for 15 s, and extension at 68°C for 90 6 s; and a final extension at 68°C for 10 min. A PCR product was incubated with Dpn I 7 (20 units) (New England Biolabs, R0176) at 37°C for 20 min to digest the template 8 NΔR plasmid. cDNA of 100-251 tau was transformed into DH5α (TOYOBO, DNA-9 903F). After the DH5a was cultured in LB medium containing 10 mg/mL of tryptone 10 (Gibco, 211705), 5 mg/mL of yeast extract (Gibco, 212750), 10 mg/mL of sodium 11 chloride (Nacalai Tesque, 31320-05), and 100 µg/mL of ampicillin (Nacalai Tesque, 12 02739-32), the cDNA was purified by NucleoSpin® Plasmid Transfection-grade

forward primer (5'-CACCATGGGAACCACAGCTGAAGAAGCAGGC-3') and 0.2

- 13 (Takara Bio Inc., 740490). The sequences of the cDNA were confirmed through DNA
- 14 sequencing (FASMAC).
- 15

1

16 **2-7-2. Cell culture**

- 17 COS-7 cells at around 90% confluence were detached from 10-cm dishes (CORNING,
- 18 353003) by trypsinization (Nacalai Tesque, 32777-15) and counted. The cells were
- 19 plated at 2.0×10^5 in a 6-well plate (CORNING, 3506). cDNAs (2.5 µg) were
- 20 transfected with Lipofectamine 3000 according to the manufacturer's instruction
- 21 (Invitrogen, L3000) 2 days after culturing. PCI-neo (Promega) was used as the empty
- 22 vector. Transfection reagents were removed by a medium change 1 day after the
- 23 transfection.
- 24

25 **2-7-3. Preparation of cell homogenate**

- 26 The cells were scraped in a buffer (1 × TBS [Nacalai Tesque, 35438-81], 1 mM EDTA
- 27 [Nacalai Tesque, 15112-22]) containing protease inhibitors (5 µg/mL of pepstatin A
- 28 [Nacalai Tesque, 26436-52, 5 μg/mL of leupeptin [Nacalai Tesque, 103476-89-7],
- 29 2 µg/mL of aprotinin [Nacalai Tesque, 03346-84], and phosphatase inhibitors [Nacalai
- 30 Tesque, 07575-51]) and homogenized for 30 s on the crashed ice using a polytron
- 31 homogenizer (NITI-ON, NS-310E). After homogenization, solutions were centrifuged
- 32 (23000 rpm, 15 min, 4°C) using a TLA55 Rotor (Beckman Coulter). The supernatants
- 33 were applied to the Bradford assay (Nacalai Tesque, 11617-71) to determine the total
- 34 protein concentration and then stored at -80 °C.
- 35

36 **2-7-4. Comparison between our mid-p-tau181 assay and the commercially**

1	available p-tau181 assay
2	Serially diluted cell homogenates, prepared as previously described, containing both N-
3	and C-terminally truncated p-tau181 were applied to our mid-p-tau181 assay
4	(Supplementary Figure 5, a solid line) and a commercially available p-tau181 assay
5	(Simoa [™] pTau-181 Advantage V2 Kit, Quanterix). Fluorescent signals converted to
6	AEB values obtained from both assays are plotted in the Supplementary Figure 5 (solid
7	line: mid-p-tau assay; broken line: commercially available p-tau181 assay). The results
8	from both assays demonstrated that AEB values were obtained in our mid-p-tau181
9	assay but not in the commercially available p-tau181 assay, indicating that our mid-p-
10	tau assay can quantify both N- and C-terminally truncated p-tau181 that could not be
11	detected with the conventional p-tau181 assay.
12	
13	3. Determining the cutoff values of temporal meta-ROI SUVR in tau PET images
14	ROC analysis was conducted using tau PET images of CN subjects and AD
15	continuum patients to determine the optimal cutoff value for the temporal meta-ROI
16	SUVR. Our analysis provided an AUC of 0.924. Moreover, based on the Youden index,
17	we obtained a sensitivity and specificity of 85.4% and 92.5%, respectively. The optimal
18	cutoff value for discrimination was determined to be 1.105.
19	
20	Satoh-Asahara N, Yamakage H, Tanaka M, Kawasaki T, Matsuura S, Tatebe H,
21	Akiguchi I, Tokuda T. Soluble TREM2 and Alzheimer-related biomarker
22	trajectories in the blood of patients with diabetes based on their cognitive
23	status. Diabetes Res Clin Pract. 2022; 193: 110121.
24	Shinomoto M, Kasai T, Tatebe H, Kitani-Morii F, Ohmichi T, Fujino Y, Allsop D,
25	Mizuno T, Tokuda T. Cerebral spinal fluid biomarker profiles in CNS infection
26	associated with HSV and VZV mimic patterns in Alzheimer's disease. Transl
27	Neurodegener. 2021; 10(1): 2.
28	Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D,
29	Tokuda T. Quantification of plasma phosphorylated tau to use as a biomarker for
30	brain Alzheimer pathology: pilot case-control studies including patients with
31	Alzheimer's disease and down syndrome. Mol Neurodegener. 2017; 12(1): 63.
32	Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu
33	N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B. Presenilin 1 associates
34	with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U
35	S A. 1998; 95(16): 9637-41.
36	

	Sample 1:	Sample 2:	Sample 3:	Sample 4:
	0.039 pg/mL	6.25 pg/mL	25.0 pg/mL	100 pg/mL
Mean AEB	0.00632	0.0580	0.224	0.872
SD	0.000222	0.000849	0.00656	0.00940
CV (%)	3.51	1.46	2.94	1.08

1 Supplementary Table 1. Intra-assay precision (n = 20).

2 AEB, average enzyme per bead; SD, standard deviation; CV, coefficient of variation.

3

4 Supplementary Table 2. Inter-assay precision for quality control samples (n = 25).

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5
Mean AEB	0.00331	0.00484	0.0592	0.128	0.882
SD	0.000184	0.000246	0.00545	0.00676	0.0526
CV (%)	5.56	5.09	9.19	5.30	5.96

⁵ AEB, average enzyme per bead; SD, standard deviation; CV, coefficient of variation.

6

7 Supplementary Table 3. Recovery rate (%Recovery) for each plasma sample in the

8 spike recovery tests.

	Treatment	Measured concentration (pg/mL)	CV (%)	Theoretical concentration of the spiked sample (pg/mL)	Recovery rate (%)
Sample 1	Neat (0 pg spike)	0.2675	14.9		
	0.15 pg spike	0.3500	7.94	0.4175	119.3
	0.3 pg spike	0.5130	12.2	0.5675	110.6
	0.6 pg spike	0.8649	7.73	0.8675	100.3
Sample 2	Neat (0 pg spike)	0.4516	6.91		
	0.15 pg spike	0.6842	3.63	0.6016	87.9
	0.3 pg spike	0.8909	5.82	0.7516	84.4
	0.6 pg spike	1.101	7.44	1.0516	95.6

- 9 CV, coefficient of variation.
- 10

11

- 12
- 13
- 14

1 Supplementary Table 4. Multiple linear regression analysis of p-tau levels with

2 amyloid and tau PET metrics.

3

	Beta coefficient	Standard error	Adjusted R ²	P-value
mid-p-tau181			L	L
Amyloid PET (Centiloid)	0.399	0.118	0.420	0.002
Tau PET (Temporal meta- ROI)	0.311	0.118		0.020
N-p-tau181				
Amyloid PET (Centiloid)	0.258	0.115	0.450	0.056
Tau PET (Temporal meta- ROI)	0.472	0.115		<0.0001

4

_

5

6

7 Supplementary Table 5. Tau PET status of cognitively normal individuals and AD

8 continuum patients through three different approaches.

9

	CN		AD	
Quantitative approach	Tau (-)	Tau (+)	Tau (-)	Tau (+)
Braak staging	35	5	3	45
Temporal meta- ROI SUVR	37	3	7	41
AD tau score	40	0	2	35

10 The cut-off values of Temporal meta-ROI SUVR and AD tau score were 1.105 and

11 0.1986, respectively. AD tau scores were exclusively computed for cases that underwent

12 imaging with the mCT PET scanner.

13

14

1	Legends for Supplementary Figures
2	Supplementary Figure 1. A schematic illustration tau protein showing the epitope
3	location of the antibodies used in this study.
4	
5	Supplementary Figure 2. Standard curve.
6	Refer "Supplementary Methods and Results", "2-1. Standard curve for the mid-p-
7	tau181 immunoassay".
8	
9	Supplementary Figure 3. Dilution linearity.
10	Refer "Supplementary Methods and Results", "2-5. Dilution linearity".
11	
12	Supplementary Figure 4. Spike recovery and parallelism.
13	Refer "Supplementary Methods and Results", "2-6. Spike recovery and
14	parallelism".
15	
16	Supplementary Figure 5. Comparison of the AEB signals between our mid-p-
17	tau181 assay and the commercially available p-tau181 assay.
18	Refer "Supplementary Methods and Results", "2-7-4. Comparison between our
19	mid-p-tau181 assay and the commercially available p-tau181 assay".
20	
21	Supplementary Figure 6. List of ROIs applied to the tau PET images.
22	From left to right, overlaid ROIs on native T1 space of representative subject: Braak
23	staging ROI, temporal meta-ROI, and AD tau score ROI. The Braak staging ROI is
24	color-coded, with Braak I/II, III/IV, and V/VI regions shown in red, yellow, and blue,
25	respectively. The temporal meta-ROI is labeled in green. The AD tau score ROI
26	represents 114 areas segmented using Mvision. Scores were derived by assigning
27	weights to diagnostically relevant areas within these ROIs.
28	
29	Supplementary Figure 7. Comparative analyses of blood biomarkers across the
30	clinical diagnosis groups and between the amyloid PET status.
31	(A) The data distribution is portrayed using scatter plots, with group differences having
32	been evaluated through the Kruskal-Wallis test. Statistically significant differences are
33	denoted as follows: $p < 0.0001$ (****), $p = 0.0004$, or 0.0010 (***), $p = 0.0070$ (**),
34	and non-significant at $p < 0.05$ (ns), as determined using Dunn's multiple comparisons.
35	(B) ROC curves were utilized to differentiate AD from other groups determined
36	according to qualitative findings of amyloid PET. The corresponding AUC values are

1 listed.

- 2 CN, cognitively normal; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;
- 3 FTLD, frontotemporal degeneration; Aβ, amyloid beta; N-p-tau181, phosphorylated
- 4 tau181 measured with the Simoa pTau-181 V2.1 Assay kit (Quanterix); mid-p-tau181,
- 5 phosphorylated tau181 measured using the originally developed immunoassay directed
- 6 to both N- and C-terminally truncated p-tau181 fragments; NfL, neurofilament light
- 7 chain; ROC, Receiver Operating Characteristic; AUC, area under the ROC curve.
- 8

9 Supplementary Figure 8. Correlations between plasma mid-p-tau levels and tau 10 PET measures in the subjects with PSP.

- 11 Correlation analysis between tau PET images and plasma mid-p-tau181 levels in
- 12 patients with PSP. Neither voxel-based (A) nor ROI-based (B and C) analyses showed a
- 13 significant correlation with tau PET accumulation. The ROI-based approach used
- 14 Pearson's correlation, with the results presented as r (correlation coefficient) and p
- 15 (statistical significance) values. PSP-tau score is a machine learning-based measure
- 16 indicating PSP-related features of tau PET images (Endo et al. 2022). Each anatomical
- 17 ROI was set in MNI space using a template atlas (Talairach Daemon atlas from the
- 18 Wake Forest University PickAtlas version 3.0.5).
- 19 SUVR, standardized uptake value ratio.
- 20
- 21
- 22
- 23